<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00325897</url>
  </required_header>
  <id_info>
    <org_study_id>397</org_study_id>
    <secondary_id>U10HL074424-03</secondary_id>
    <nct_id>NCT00325897</nct_id>
  </id_info>
  <brief_title>Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Effect of Chronic Macrolide Administration on the Frequency and Severity of COPD Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if long-term administration of a macrolide
      antibiotic will reduce worsening of symptoms among individuals with chronic obstructive
      pulmonary disease (COPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      The prevalence, morbidity, mortality, and treatment cost of COPD are high and increasing.
      COPD is the sixth leading cause of death worldwide and is the only condition in the top 10
      causes of death that has an increasing prevalence and mortality. The cost of health care for
      patients with COPD in the U.S. is approximately $6.5 billion per year; acute exacerbations
      account for between 31% and 68% of that cost. Macrolide antibiotics may reduce the frequency
      and/or severity of COPD exacerbations, as a result of their antibacterial properties and
      anti-inflammatory effects. Long-term administration of macrolide antibiotics in patients with
      a number of other pulmonary disorders has resulted in clinically important improvements. It
      is hypothesized that administration of a macrolide antibiotic (azithromycin) for 1 year, when
      added to usual care, will decrease the frequency and severity of COPD exacerbations. If this
      hypothesis is correct, the proposed treatment is also expected to reduce the mortality of
      COPD patients.

      DESIGN NARRATIVE:

      This is a prospective, randomized, double-blind, placebo-controlled study that will enroll
      1130 patients with at least moderately severe COPD who, based on clinical indicators, have an
      increased likelihood of experiencing an acute exacerbation during the study period. Patients
      will be monitored monthly, including careful assessments of possible macrolide-related side
      effects. The exclusion criteria for this study will include a variety of conditions or
      medications that are known to adversely interact with macrolides. The primary endpoint of
      this study is time until the first acute COPD exacerbation. The secondary endpoints include
      macrolide-related side effects, the incidence of macrolide-resistant bacterial colonization,
      quality of life, and cost-effectiveness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time Until First Occurrence of Acute Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</measure>
    <time_frame>Measured monthly through 13 months</time_frame>
    <description>Time until first occurrence of acute Chronic Obstructive Pulmonary Disease (COPD) exacerbation. Acute exacerbations are defined as a &quot;complex of respiratory symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnea, or chest tightness with a duration of at least three days requiring treatment with antibiotics and/or systemic steroids &quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exacerbations/Patient Year</measure>
    <time_frame>Measured monthly until 13 months</time_frame>
    <description>Acute exacerbations are defined as a &quot;complex of respiratory symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnea, or chest tightness with a duration of at least three days requiring treatment with antibiotics and/or systemic steroids &quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Emergency Department Visits as a Result of Acute Exacerbations</measure>
    <time_frame>Measured monthly for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospital Admissions as a Result of Acute Exacerbations</measure>
    <time_frame>Measured monthly for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Age-adjusted Hearing Threshold</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Assessed by audiometry for four sound frequencies (1000, 2000, 3000, 4000 Hz). The maximum was computed for each threshold in each ear for all frequencies, then the differences between visits were assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Macrolide-resistant Bacterial Colonization of the Nasopharynx or Sputum</measure>
    <time_frame>Baseline</time_frame>
    <description>Cultures from 68% of the participants in the azithromycin group and 70% in the placebo group who were not colonized with selected respiratory pathogens at the time of enrollment but who became colonized during the course of the study were available for susceptibility testing for the incidence of macrolide-resistant bacterial colonization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Macrolide-resistant Bacterial Colonization of the Nasopharynx or Sputum</measure>
    <time_frame>During Course of Study (either month 3, 6, 9, or 12)</time_frame>
    <description>Cultures from some participants who were not colonized with selected respiratory pathogens at the time of enrollment but who became colonized during the course of the study were available for susceptibility testing for the incidence of macrolide-resistant bacterial colonization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1142</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Azithromycin, 250 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Macrolide Antibiotic (Azithromycin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macrolide Antibiotic (Azithromycin)</intervention_name>
    <description>Azithromycin (daily capsule, 250 mg for 12 months)</description>
    <arm_group_label>Azithromycin, 250 mg</arm_group_label>
    <other_name>Zithromax</other_name>
    <other_name>Zmax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo taken on a daily basis</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of at least moderate Chronic Obstructive Pulmonary Disease (COPD),
             as defined by the following Global Initiative for COPD (GOLD) criteria:

               1. Post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital
                  capacity (FVC) ratio of less than 70%

               2. Post-bronchodilator FEV1 less than 80% predicted, with or without chronic
                  symptoms

          -  Cigarette consumption of 10 pack-years or more (may or may not be active smokers)

          -  Meets one or more of the following four conditions:

               1. Current, or history of, supplemental O2 use

               2. Received a course of systemic corticosteroids for respiratory problems within 1
                  year prior to study entry

               3. Visited an emergency department for a COPD exacerbation within 1 year prior to
                  study entry

               4. Hospitalized for a COPD exacerbation within 1 year prior to study entry

          -  Willing to make return visits

          -  Available by telephone for duration of study

          -  Minimum of 4 weeks from the most recent acute exacerbation (have not received a course
             of systemic corticosteroids, an increased dose of chronically administered systemic
             corticosteroids, and/or antibiotics for an acute exacerbation for a minimum of 4 weeks
             from the time of study entry)

        Exclusion Criteria:

          -  Diagnosis of asthma

          -  Diagnosis other than COPD that results in the patient being either medically unstable,
             or having a predicted life expectancy less than 3 years

          -  Special patient groups (i.e., prisoners, pregnant women, or institutionalized
             patients)

          -  Women who are at risk of becoming pregnant during the study (pre-menopausal) and who
             refuse to use acceptable birth control (i.e., hormone-based oral or barrier
             contraceptive) for the duration of the study

          -  History of hypersensitivity to any macrolide antibiotic

          -  Taking any of the following medications:

               1. Cisapride

               2. Ergot derivatives

               3. Pimozide

               4. Disopyramide

               5. Cyclosporin

               6. Tacrolimus

               7. Nelfinavir

               8. Bromocriptine

               9. Hexobarbital

          -  Corrected QT interval (QTc) on electrocardiogram exceeding 440 ms

          -  Taking rifabutin or rifampin

          -  Chronic hepatic insufficiency

          -  Chronic renal insufficiency

          -  Diagnosis of bronchiectasis (defined as production of greater than one-half cup of
             purulent sputum/day)

          -  If, for either ear, formal audiometric testing in a sound booth results in a pure tone
             average (i.e., the average of the thresholds for the 4 frequencies 1000, 2000, 3000,
             or 4000) exceeding 50 decibel (dB), or if the threshold at any one frequency exceeds
             60 dB, then the participant will be counseled by the audiologist concerning hearing
             aids and/or referral to an otolaryngologist. In addition, the audiologist may discuss
             with the participant whether or not to continue in the study. Following the
             examination and counseling, the participant will also discuss whether or not to
             continue in the study with one of the study investigators. If it is found that a
             participant's pure tone average in the two ears differs by more than 15 dB, or if the
             difference in the two ears for any one frequency exceeds 20 dB, then the participant
             will not be eligible for randomization into the study unless cleared by an
             otolaryngologist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard K. Albert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver City-County Health/Hospitals Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William C. Bailey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Casaburi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harbor-UCLA Research &amp; Education Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John E. Connett, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota, MN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerard J. Criner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen C. Lazarus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California at San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando J. Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis E. Niewoehner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minnesota Veterans Medical Research and Education Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John J. Reilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven M. Scharf, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Sciurba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Research &amp; Education Inst.</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver City-County Health/Hospitals Dept.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Veterans Research Inst.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55440</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/21864166</url>
    <description>Published manuscript reporting main results</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2006</study_first_submitted>
  <study_first_submitted_qc>May 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2006</study_first_posted>
  <results_first_submitted>August 18, 2011</results_first_submitted>
  <results_first_submitted_qc>May 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 7, 2012</results_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Azithromycin</title>
          <description>Azithromycin, 250 mg</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Inactive sugar pill</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="570"/>
                <participants group_id="P2" count="572"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="558"/>
                <participants group_id="P2" count="559"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azithromycin</title>
          <description>Azithromycin, 250 mg</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Inactive sugar pill</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="570"/>
            <count group_id="B2" value="572"/>
            <count group_id="B3" value="1142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="311"/>
                    <measurement group_id="B3" value="604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8" spread="8.7"/>
                    <measurement group_id="B2" value="65.5" spread="8.4"/>
                    <measurement group_id="B3" value="65.1" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="229"/>
                    <measurement group_id="B3" value="463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="336"/>
                    <measurement group_id="B2" value="343"/>
                    <measurement group_id="B3" value="679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="559"/>
                    <measurement group_id="B2" value="558"/>
                    <measurement group_id="B3" value="1117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>All applicable categories were checked for each participant.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="463"/>
                    <measurement group_id="B2" value="457"/>
                    <measurement group_id="B3" value="920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="570"/>
                    <measurement group_id="B2" value="572"/>
                    <measurement group_id="B3" value="1142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time Until First Occurrence of Acute Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
        <description>Time until first occurrence of acute Chronic Obstructive Pulmonary Disease (COPD) exacerbation. Acute exacerbations are defined as a &quot;complex of respiratory symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnea, or chest tightness with a duration of at least three days requiring treatment with antibiotics and/or systemic steroids &quot;</description>
        <time_frame>Measured monthly through 13 months</time_frame>
        <population>Participants that had any follow-up data were included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin</title>
            <description>Azithromycin 250 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Time Until First Occurrence of Acute Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
          <description>Time until first occurrence of acute Chronic Obstructive Pulmonary Disease (COPD) exacerbation. Acute exacerbations are defined as a &quot;complex of respiratory symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnea, or chest tightness with a duration of at least three days requiring treatment with antibiotics and/or systemic steroids &quot;</description>
          <population>Participants that had any follow-up data were included in analysis.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="559"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266" lower_limit="227" upper_limit="313"/>
                    <measurement group_id="O2" value="174" lower_limit="143" upper_limit="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exacerbations/Patient Year</title>
        <description>Acute exacerbations are defined as a &quot;complex of respiratory symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnea, or chest tightness with a duration of at least three days requiring treatment with antibiotics and/or systemic steroids &quot;</description>
        <time_frame>Measured monthly until 13 months</time_frame>
        <population>Participants with any follow-up data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin</title>
            <description>Azithromycin, 250 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Exacerbations/Patient Year</title>
          <description>Acute exacerbations are defined as a &quot;complex of respiratory symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnea, or chest tightness with a duration of at least three days requiring treatment with antibiotics and/or systemic steroids &quot;</description>
          <population>Participants with any follow-up data were analyzed.</population>
          <units>exacerbations/patient year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="559"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48"/>
                    <measurement group_id="O2" value="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Emergency Department Visits as a Result of Acute Exacerbations</title>
        <time_frame>Measured monthly for 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin</title>
            <description>Azithromycin, 250 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Emergency Department Visits as a Result of Acute Exacerbations</title>
          <units>Visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
                <count group_id="O2" value="572"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospital Admissions as a Result of Acute Exacerbations</title>
        <time_frame>Measured monthly for 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin</title>
            <description>Azithromycin 250 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospital Admissions as a Result of Acute Exacerbations</title>
          <units>Hospitalizations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
                <count group_id="O2" value="572"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Age-adjusted Hearing Threshold</title>
        <description>Assessed by audiometry for four sound frequencies (1000, 2000, 3000, 4000 Hz). The maximum was computed for each threshold in each ear for all frequencies, then the differences between visits were assessed.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Participants with both baseline and one-year audiometry data available were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin, 250 mg</title>
            <description>Macrolide Antibiotic (Azithromycin)
Macrolide Antibiotic (Azithromycin): Azithromycin (daily capsule, 250 mg for 12 months)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive
Placebo: Placebo taken on a daily basis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Age-adjusted Hearing Threshold</title>
          <description>Assessed by audiometry for four sound frequencies (1000, 2000, 3000, 4000 Hz). The maximum was computed for each threshold in each ear for all frequencies, then the differences between visits were assessed.</description>
          <population>Participants with both baseline and one-year audiometry data available were analyzed.</population>
          <units>Decibels (db)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="4.2"/>
                    <measurement group_id="O2" value="-0.9" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Macrolide-resistant Bacterial Colonization of the Nasopharynx or Sputum</title>
        <description>Cultures from 68% of the participants in the azithromycin group and 70% in the placebo group who were not colonized with selected respiratory pathogens at the time of enrollment but who became colonized during the course of the study were available for susceptibility testing for the incidence of macrolide-resistant bacterial colonization.</description>
        <time_frame>Baseline</time_frame>
        <population>Using cultures from participants who were not colonized with selected respiratory pathogens at the time of enrollment but who became colonized during the course of the study, samples were available from 68% of the participants in the azithromycin group and 70% in the placebo group among these cultures.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin, 250 mg</title>
            <description>Macrolide Antibiotic (Azithromycin)
Macrolide Antibiotic (Azithromycin): Azithromycin (daily capsule, 250 mg for 12 months)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive
Placebo: Placebo taken on a daily basis</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Macrolide-resistant Bacterial Colonization of the Nasopharynx or Sputum</title>
          <description>Cultures from 68% of the participants in the azithromycin group and 70% in the placebo group who were not colonized with selected respiratory pathogens at the time of enrollment but who became colonized during the course of the study were available for susceptibility testing for the incidence of macrolide-resistant bacterial colonization.</description>
          <population>Using cultures from participants who were not colonized with selected respiratory pathogens at the time of enrollment but who became colonized during the course of the study, samples were available from 68% of the participants in the azithromycin group and 70% in the placebo group among these cultures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Macrolide-resistant Bacterial Colonization of the Nasopharynx or Sputum</title>
        <description>Cultures from some participants who were not colonized with selected respiratory pathogens at the time of enrollment but who became colonized during the course of the study were available for susceptibility testing for the incidence of macrolide-resistant bacterial colonization.</description>
        <time_frame>During Course of Study (either month 3, 6, 9, or 12)</time_frame>
        <population>Using cultures from participants who were not colonized with selected respiratory pathogens at the time of enrollment but who became colonized during the course of the study, samples were available from 68% of the participants in the azithromycin group and 70% in the placebo group among these cultures.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin, 250 mg</title>
            <description>Macrolide Antibiotic (Azithromycin)
Macrolide Antibiotic (Azithromycin): Azithromycin (daily capsule, 250 mg for 12 months)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inactive
Placebo: Placebo taken on a daily basis</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Macrolide-resistant Bacterial Colonization of the Nasopharynx or Sputum</title>
          <description>Cultures from some participants who were not colonized with selected respiratory pathogens at the time of enrollment but who became colonized during the course of the study were available for susceptibility testing for the incidence of macrolide-resistant bacterial colonization.</description>
          <population>Using cultures from participants who were not colonized with selected respiratory pathogens at the time of enrollment but who became colonized during the course of the study, samples were available from 68% of the participants in the azithromycin group and 70% in the placebo group among these cultures.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>13 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Azithromycin</title>
          <description>Azithromycin, 250 mg</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Inactive sugar pill</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD-9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="572"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="570"/>
                <counts group_id="E2" events="36" subjects_affected="31" subjects_at_risk="572"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Digestive</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="570"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="572"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="113" subjects_affected="100" subjects_at_risk="570"/>
                <counts group_id="E2" events="114" subjects_affected="101" subjects_at_risk="572"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="570"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="572"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="570"/>
                <counts group_id="E2" events="41" subjects_affected="37" subjects_at_risk="572"/>
              </event>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" events="145" subjects_affected="120" subjects_at_risk="570"/>
                <counts group_id="E2" events="170" subjects_affected="109" subjects_at_risk="572"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>ICD-9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="500" subjects_at_risk="570"/>
                <counts group_id="E2" subjects_affected="444" subjects_at_risk="572"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory</sub_title>
                <counts group_id="E1" events="49" subjects_affected="34" subjects_at_risk="570"/>
                <counts group_id="E2" events="42" subjects_affected="29" subjects_at_risk="572"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Digestive</sub_title>
                <counts group_id="E1" events="89" subjects_affected="62" subjects_at_risk="570"/>
                <counts group_id="E2" events="104" subjects_affected="78" subjects_at_risk="572"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1132" subjects_affected="319" subjects_at_risk="570"/>
                <counts group_id="E2" events="1176" subjects_affected="331" subjects_at_risk="572"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="570"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="572"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="570"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="572"/>
              </event>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" events="566" subjects_affected="185" subjects_at_risk="570"/>
                <counts group_id="E2" events="657" subjects_affected="244" subjects_at_risk="572"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Richard Albert</name_or_title>
      <organization>Denver Health Medical Center</organization>
      <phone>303-436-6900</phone>
      <email>ralbert@dhha.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

